DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for benign neoplasm of parathyroid gland — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBenign neoplasm of parathyroid gland maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for benign neoplasm of parathyroid gland is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
MLLT10 histone lysine methyltransferase DOT1L cofactor (MLLT10) — MLLT10 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6CKO · 2.0 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
A 2016 case report describes parathyroid cancer in a patient with relapsing secondary hyperparathyroidism four years after subtotal parathyroidectomy. The case also involved parathyromatosis and ectopic adenomatous hyperplastic parathyroid tissue within the thyroid gland. The authors note the complexity of surgical strategy and of morphological and cytological diagnosis in this setting. No drug treatment is mentioned.
A 1992 series of nine parathyroid tumour cases included seven patients with parathyroid hyperplasia secondary to chronic renal failure and two with adenomas. The authors state that total parathyroidectomy with autologous retransplantation is one of the best surgical approaches. They report that preoperative CT and echogram indicated the number and location of glands, but that more precise examination was needed to avoid false negatives. No drug therapy is discussed.
A 2013 textbook chapter reviews the molecular genetic basis of parathyroid tumour formation in heritable and sporadic disorders, including multiple endocrine neoplasia types 1 and 2. It notes that a major effect of parathyroid neoplasia is disruption of gland physiology, and that this is relevant to modern molecular-targeted therapeutics. No specific drug, trial, or clinical outcome data are provided.
No randomised trials, drug interventions, or quantitative efficacy data for any pharmacological treatment of benign parathyroid neoplasms appear in these abstracts. What is missing is any clinical trial testing a repurposed drug, a defined patient stratification strategy, and funding for such a study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1962 · 52 citations
Functioning Lipoadenoma of the Parathyroid Gland
AbstractA UNIQUE functioning tumor of the parathyroid gland was found in a forty-one-year-old man with clinical hyperparathyroidism. It was composed of a blend of fibrofatty lobules and trabeculae and sheets of parathyroid chief cells. The only similar reported case is that of Ober and Kaiser,1 who described a nonfunctioning, large, encapsulated mass composed of an admixture of fibrofatty and parathyroid tissues that they designated as hamartoma of the parathyroid gland. It differed from our case only in the absence of endocrine dysfunction and the presence of all types of parathyroid cells in the tumor.Case ReportN.R.S., a 41-year-old man, . . .
Almanac of Clinical Medicine · 2016 · 2 citations · open access
PARATHYROID CANCER OCCURRING IN RELAPSING SECONDARY HYPERPARATHYROIDISM
AbstractWe present a clinical case of parathyroid cancer in a patient with relapsing secondary hyperparathyroidism at 4 years after subtotal parathyroidectomy. Its unique character is related to the combination of relapsing secondary hyperparathyroidism, parathyromatosis, ectopic of an adenomatous hyperplastic parathyroid gland into the thyroid gland, and parathyroid cancer. Several most complicated aspects of parathyroid surgery are disclosed, such as the choice of strategy for surgical intervention in secondary hyperparathyroidism, complexity of morphological and cytological diagnostics of this disorder.
Practica Oto-Rhino-Laryngologica · 1992 · 0 citations · open access
Surgical Resection of Parathyroid Tumor.
AbstractWe present nine cases of parathyroid tumor, and a review of the literature on surgical treatment. In seven patients, the histologic diagnosis was parathyroid hyperplasia, which were observed in patients with secondary hyperplasia due to chronic renal failure. The other two patients had adenomas. The preoperative examination with computed tomography (CT) and echogram indicated the number and location of the parathyroid glands. However, more precise preoperative examination was necessary to avoid a false negative diagnosis. In our experience, total parathyroidectomy and retransplantation of autologous parathyroid tissue is one of the best surgical approaches.
AbstractIn this chapter we will examine the molecular genetic basis of parathyroid gland tumorigenesis across a spectrum of heritable and sporadic disorders (Table 65.1). Two genetic predispositions to parathyroid (and other) tumors, multiple endocrine neoplasia types 1 and 2, are addressed in a separate chapter. We begin with a brief review of parathyroid gland physiology, because a major effect of parathyroid neoplasia involves its disruption, and because of its relevance to modern molecular-targeted therapeutics.
Korean Journal of Otorhinolaryngology - Head and Neck Surgery · 2021 · 0 citations · open access
A Case of Intrathyroidal Parathyroid Carcinoma Accompanied by Contralateral Parathyroid Hyperplasia
AbstractParathyroid carcinoma accounts for about 0.5%-5% of all parathyroid neoplasms. Very rarely, but if the intrathyroidal parathyroid gland is present, the carcinoma can arise in that developmental anomaly. It is very difficult to distinguish a thyroid nodule from an intrathyroidal parathyroid neoplasm with preoperative radiologic and cytologic evaluations. A 59-year-old male was initially evaluated as presenting a follicular thyroid neoplasm accompanied by hyperparathyroidism. He received hemi-thyroidectomy with central neck dissection and subtotal parathyroidectomy. The final pathology evaluation revealed intrathyroidal parathyroid carcinoma and hyperplasia of contralateral parathyroid glands. We report this very rare and unique clinical situation with a literature review.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
